RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
Interview: Infusing the Patient Perspective into Value Assessment, Part I
Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In this segment, our experts kick off a three-part series about patient perspective in value assessment with an overview of value assessments and value frameworks.
Interview: Senior Health and Well-Being During COVID-19
Tune into another episode in the Avalere Health Essential Voice podcast series focused on COVID-19. In this segment, Richard Ashworth, President and CEO of Tivity Health, joins us to discuss survey findings around COVID-19 and the senior population, with key takeaways related to vaccination acceptance and hesitancy.
Medicare FFS Utilization Decreased During the COVID-19 Pandemic
Avalere analysis finds healthcare utilization among Medicare Fee-for-Service (FFS) beneficiaries decreased in the spring of 2020 compared to the spring of 2019.
A Data-Driven Approach to Identifying Patients with AAD
On November 4, Avalere experts presented “Development of a Claims-Based Algorithm to Identify Patients with Agitation in Alzheimer’s Dementia” at the Gerontological Society of America Annual Scientific Meeting.
COVID-19 Impacts on Cancer Care
Avalere research was published online in the Journal of Clinical Oncology Clinical Cancer Informatics, showing a considerable drop in cancer screening, diagnosis, and treatment for Medicare beneficiaries as a result of the ongoing COVID-19 pandemic.
Hospital Discharges to Home Health Rebounding, But SNF Volumes Lag
New Avalere Health analysis of Medicare fee-for-service (FFS) claims data reveals large decreases in skilled nursing facility (SNF) and home health care use following the widespread decline in inpatient hospitalizations amid the response to the COVID-19 pandemic. Avalere’s analysis further suggests that as inpatient procedures resume in some areas, the volume of inpatient hospital discharges to home health is starting to rebound, whereas the volume of discharges to SNF remains below 2019 levels.
New Data Approaches for Novel Curative Therapies and APMs
On June 9, Avalere experts discussed new data analytics and approaches for evaluating value-based topics in healthcare in the “New Data Approaches for Novel Curative Therapies & APMs” webinar. They examined the current approaches to assessing the value of treatments, novel curative therapy affordability and access, and the role of data in healthcare decision-making.
COVID-19 Hospitalizations Projected to Cost up to $17B in US in 2020
Avalere analysis of Medicare fee-for-service (FFS) hospital stay claims with associated COVID-19 diagnoses finds that total US healthcare system costs for hospitalizations due to COVID-19 could range from $9.6B to $16.9B in 2020.
Decline in Oncology and Immunology Treatment Amid COVID-19 Pandemic
Recent Avalere analysis finds decreases in utilization of oncology and autoimmune treatments across all care settings since the onset of the health crisis.
COVID-19 Compass
COVID-19 continues to spread nationwide, and individuals with social risk factors and underlying chronic conditions are at highest risk for severe illness.
Webinar: New Data Analytics Approaches for Novel Curative Therapies & APMs
Avalere experts discussed new data analytics and health economics and outcomes research approaches for evaluating key value-based topics in healthcare, including novel curative therapy affordability and access, alternative payment models, and the increasingly important role of real-world evidence in healthcare decision-making.
The Burden and Costs of Recurrent Clostridioides Difficile
Recurring episodes of clostridioides difficile (c diff) create significant added healthcare burden and costs to society and lead to avoidable adverse outcomes in the Medicare population
COVID-19 Complicates Access to Provider-Administered Autoimmune Treatments
The large-scale disruptions resulting from COVID-19 are significantly reshaping how patients receive care. In particular, patients taking infused and injectable drugs administered by a healthcare professional at a physician office, infusion center, or hospital outpatient department now face greater challenges receiving their medications.
Interview: E6 – Get the Facts on COVID-19: Oncology Care and Delivery
Avalere experts discuss how the COVID-19 pandemic has affected oncology care and delivery, and the Oncology Care Model (OCM).
Webinar: Guiding Patients on Care Journeys: Preparing for Shared Decision-Making
Experts from Avalere and the National Patient Advocate Foundation (NPAF) discussed the value of shared decision-making (SDM) and preparing patients and families for navigating their care journeys.
An Update on the Preparation for Shared Decision-Making Tool for Stage III Non-Small Cell Lung Cancer Patients
Avalere published an abstract in the online Journal of National Comprehensive Cancer Network (JNCCN).
Avalere Health Partners with Leading Registry and Analytics Company, Corrona LLC, to Combine Economic and Clinical Outcomes Data for Autoimmune Diseases
The collaboration leverages the Inovalon MORE2 Registry® payer-sourced dataset and Corrona’s platform of clinical registries to enable data-driven insights on the treatment of autoimmune diseases from both clinical and health economic perspectives.
Patient Registries Can Pave the Way to Establishing a Learning Health System
As the shape and scope of America’s learning health system evolves, Avalere partners with industry leaders, engaging multiple stakeholders to formulate patient registry strategies that develop, evaluate, and utilize registry data – and help improve care in real time.
Medication Adherence Rates Low Among Patients with Serious Mental Illness
Avalere research recently published in ClinicoEconomics and Outcomes Research compared patient characteristics and real-world outcomes in 2 distinct high-risk cohorts of patients with serious mental illness (SMI), including patients with a hospitalization related to SMI (recently discharged) and patients newly diagnosed with SMI (early episode). The research included 51,705 patients with bipolar disorder, major depressive disorder, and schizophrenia.
Avalere Publishes Manuscript on Validating Preparation for Shared Decision-Making Tool for Advanced Breast Cancer Patients
Avalere’s “Preparation for Shared Decision-Making” (PFSDM) tool aims to help patients with advanced breast cancer (ABC) feel prepared to communicate with their clinicians and engage in decision making aligned with their preferences. The validation study confirms the acceptability and usability of the tool for women with ABC.